8-K: Paratek Pharmaceuticals to Acquire OptiNose in $9.00 Per Share Cash and CVR Deal

OptiNose enters into a definitive agreement to be acquired by Paratek Pharmaceuticals for $9.00 per share in cash plus a contingent value right.

Summary

• OptiNose, Inc. has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, Inc.
• Under the terms of the agreement, Paratek will acquire OptiNose for $9.00 per share in cash plus one contingent value right (CVR) per share.
• The CVR entitles OptiNose shareholders to receive additional cash payments based on the achievement of certain net sales milestones for XHANCE.
• The first milestone payment is $1.00 per CVR if XHANCE achieves net sales of $150 million in any calendar year up to December 31, 2028.
• The second milestone payment is $4.00 per CVR if XHANCE achieves net sales of $225 million in any calendar year up to December 31, 2029.
• The transaction is subject to customary closing conditions, including approval by OptiNose stockholders and regulatory approvals.
• The deal is expected to close in the second or third quarter of this year.
• MVM Partners LLC, holding approximately 9.6% of OptiNose's outstanding shares, has entered into a voting agreement with Paratek to vote in favor of the merger.
• Directors and executive officers of OptiNose have also entered into voting agreements to support the transaction.
• Paratek has obtained equity and debt financing commitments to fund the acquisition, including approximately $275 million in debt financing.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition provides OptiNose shareholders with immediate cash value and potential future upside through the CVR. The deal appears well-financed and supported by key stakeholders.

Positives

• OptiNose stockholders will receive $9.00 per share in cash, providing immediate value.
• The CVR offers the potential for additional payments based on the future performance of XHANCE.
• The acquisition provides OptiNose with access to Paratek's resources and expertise.
• Major shareholders and key personnel are supporting the transaction, increasing the likelihood of approval.

Negatives

• The CVR payments are contingent and may not be realized if XHANCE does not meet the specified sales targets.
• Pharmakon warrants will be cancelled for no consideration.
• There is a risk that the deal may not close due to failure to satisfy closing conditions.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Necessary regulatory approvals may not be obtained.
• OptiNose stockholders may not approve the acquisition.
• Milestones necessary for CVR payments may not be achieved.
• The pending merger may disrupt business and operational relationships.
• The merger may divert management's attention from ongoing business operations.
• The announcement or consummation of the merger may negatively affect the market price of OptiNose's common stock.
• Significant transaction costs may be incurred.
• Unknown liabilities may arise.
• Litigation, including shareholder litigation, and/or regulatory actions may occur.

Future Outlook

The parties anticipate that the Merger will be consummated in the second or third quarter of this year, subject to the satisfaction of closing conditions.

Industry Context

This announcement reflects ongoing consolidation trends within the pharmaceutical industry, particularly among companies with complementary therapeutic focuses.

Comparison to Industry Standards

• Contingent Value Rights (CVRs) are often used in pharmaceutical acquisitions to bridge valuation gaps and share the risk and reward associated with the future performance of a drug or product.
• The structure of this deal, with an upfront cash payment and CVRs tied to sales milestones, is a fairly common approach in the biopharmaceutical industry.
• Comparable companies that have used CVRs in acquisitions include Sanofi's acquisition of Bioveris and Bristol-Myers Squibb's acquisition of Celgene.

Stakeholder Impact

• OptiNose stockholders will receive $9.00 per share in cash and a CVR.
• OptiNose employees may experience changes in their roles and responsibilities following the acquisition.
• The acquisition may impact OptiNose's relationships with its customers, suppliers, and other business partners.

Next Steps

• Obtain OptiNose stockholder approval.
• Secure necessary regulatory approvals.
• Satisfy all other customary closing conditions.
• Consummate the Merger in the second or third quarter of this year.

Key Dates

Keywords

acquisition, merger, optinose, paratek, cvr, xhance, stockholder approval, net sales, contingent value right, pharmaceuticals